Items tagged with Pharma industry
WHO Director questions IP rights, drug prices, industry influence (post)
Saying she could speak more freely outside of the World Health Organization, WHO Director General Margaret Chan today told a gathering of think tank representatives at the Graduate Institute of Geneva that intellectual property rights may be unfairly driving up drug prices and that industry lobbying may be interfering with governments’ efforts to take action on behalf of their citizens’ public health.
GSK eases intellectual property rights for poorest countries (post)
March 31, 2016 - As the United Nations Secretary General’s High-Level Panel on Access to Medicines initiative continues its work, the GlaxoSmithKline company today announced steps to further help bring innovative medicines to poor countries.
New incentives needed to develop antibiotics to fight superbugs (post)
- Drugmakers are renewing efforts to develop medicines to fight emerging antibiotic-resistant bacteria, but creating new classes of drugs on the scale needed is unlikely to happen without new financial incentives to make the effort worth the investment, companies and industry experts said.
UN development agency issues guidelines for pharmaceutical patent examiners (post)
A new set of guidelines for pharmaceutical patent examination has been published by the United Nations Development Programme that seek to help reduce poor quality patents and ensure efficient market entry of generic products.
No time to wait: Lack of funding for TB drug research threatens projects (post)
Research into desperately needed new tuberculosis (TB) drugs is flagging because governments and pharmaceutical companies are not investing enough in the field, scientists warned on the eve of the 21st International AIDS conference, which begins on Monday (July 18).
Pricing dispute hits supply of TB drugs in Pakistan (post)
Swiss pharmaceuticals firm Novartis AG said it has stopped making tuberculosis drugs in Pakistan in a dispute over pricing, prompting fears of a health crisis due to a shortage of drugs in a country with the world's fifth-highest TB rates.
The U.S. is standing in the way of cheaper drugs for the poor (post)
Every few months, a drug company gets caught cranking up prices. Most recently, Mylan, the maker of EpiPen, took its turn in the hot seat for raising the price of a lifesaving allergy treatment by 500 percent. Congress was rightly enraged and opened yet another inquiry into pharmaceutical price gouging. Mylan offered discount coupons.
Access to Medicine Index 2016 released (post)
The Access to Medicine Index 2016 was published today (November 14), analysing the top 20 research-based pharmaceutical companies. The index looks at how those companies make medicines, vaccines and diagnostics more accessible in low- and middle-income countries. The index found progress in companies’ efforts to improve access but little support for flexibilities enshrined in international trade rules.
Africa: Dying from lack of medicines (post)
Approximately 1.6 million Africans died of malaria, tuberculosis and HIV-related illnesses in 2015. These diseases can be prevented or treated with timely access to appropriate and affordable medicines, vaccines and other health services. But less than 2% of drugs consumed in Africa are produced on the continent, meaning that many sick patients do not have access to locally produced drugs and may not afford to buy the imported ones.
WHO studies on local pharma production provide key contrasts between China, India (post)
Two new studies published by the World Health Organization provide insight on the production of pharmaceutical products in India and China. According to the studies, China has a substantial local pharmaceutical manufacturing sector which the Chinese government is closely linking to its policy objective of universal health care. India, the main global provider of generic medicines is not pursuing a comparable focus on universal health care. India is increasingly faced with Chinese pharmaceutical sector competition, with China being its main provider of commoditized active pharmaceutical ingredients (APIs).
Page 5 of 9 · Total posts: 0
←First 4 5 6 Last→